Navigation Links
Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
Date:11/8/2007

TOKYO and RIDGEFIELD, Conn., Nov. 8 /PRNewswire/ -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).

As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.

For more information, please contact:

Kate O'Connor, Communications & Public Relations

Boehringer Ingelheim Pharmaceuticals, Inc.

Tel: 203-791-6250

Mobile: 917-446-7400

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

http://www.astellas.com


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
4. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
6. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
7. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
8. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
9. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
10. Zimmer Announces Settlement of Federal Investigation
11. Martek Announces Settlement of OmegaTech Milestone Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Whitehouse, NJ (PRWEB) , ... January 18, 2017 ... ... access to more and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), ... doubled in the past year and is planned for further growth in 2017. ...
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the publishing of the latest paper by its Science Editor, Dr. Elisabeth Bik, ... Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her ...
(Date:1/18/2017)...  HUYA Bioscience International, (HUYA), the leader in accelerating ... pharmaceutical innovations, announced today a strategic collaboration agreement with ... (referred to as CAS Innovation). The collaboration will focus ... scientists at CAS to meet the medical needs of ... first company to have recognized China,s ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the addition ... offering. The report forecasts the global military biometrics market ... The report has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):